Abstract
AbstractSurgery has been combined with chemotherapy to treat osteosarcoma. However, the recovery rate of osteosarcoma patients is still low. To prevent post‐operative recurrence of the osteosarcoma, developing an alternative biomaterial is essential. 18β‐Glycyrrhetinic acid (GA) has shown potential anticancer activity in various malignancies. Here it is proposed that GA can induce osteosarcoma cell apoptosis, and a polydopamine‐mediated titanium oxide nanorod (TiO2NR) surface is functionalized by covalently grafting the chitosan‐18β‐glycyrrhetinic acid conjugate (CS–GA). In vitro and in vivo biological tests indicate that the CS–GA modified surface shows significant antiproliferation and apoptosis in osteosarcoma cells (MG63). Additionally, this modified surface with nanoarray structure stimulation and chitosan supplementation significantly promotes osteoblast (MC3T3‐E1) adhesion and proliferation in vitro. This dual‐functional, Ti‐based implant with balanced antitumor and biocompatibility properties represents an effective strategy for the surgical treatment of osteosarcoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
